-- Companies attempt to adapt to the new reality of the evolving healthcare landscape
MOUNTAIN VIEW, California, Sept. 25, 2012 /PRNewswire/ -- The medical device industry continues to be one of the most vital and dynamic sectors of the U.S. economy and a leading force in the revolution that is transforming the U.S. healthcare system. However, the industry is undergoing a transition to adapt to new business models that are changing the way care is delivered and paid for in the United States.
New analysis from Frost & Sullivan's (http://www.medicaldevices.frost.com) 2012 United States Medical Devices Outlook finds total market revenues in 2011 were $102.1 billion, with a forecast of $156.8 billion projected in 2018. The overall compound annual growth rate (CAGR) for the forecast period is a modest 6.3 percent. While top-line growth is a virtual certainty, cost-containment initiatives in the healthcare industry are forcing pricing pressure with a medical device excise tax to go into effect in 2013 that could strain margins for most companies.
For the full multimedia experience of this release, please send an email to Britni Myers, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"In retrospect, the medical device market witnessed unprecedented growth between 1995 and 2005. New technologies helped spur a revolution with minimally invasive tools and implants that improved function and safety," said Frost & Sullivan Advanced Medical Technologies Industry Manager Venkat Rajan. "These novel developments allowed for new treatments and an expansion of addressable conditions."
That growth, coupled with the potential impact of the baby boomer population, led many in the industry to assume that the marketplace was recession-resilient, if not recession-proof. However, the impact of the global economic crisis in 2008 combined with healthcare reform measures aimed at cost containment have significantly altered those expectations. In order to better align with the realities of the current market, a number of companies have undergone significant restructuring, such as major divestitures, staff cuts, and turnover in senior management.
"In spite of the challenges, that is not to say that there are not significant opportunities in the market that can be taken advantage of," said Rajan. "A historic surge in demand resulting from an aging population with escalating incidence rates for chronic disease is creating new needs and customer requirements. Furthermore, significant research breakthroughs and leaps in technology are drastically advancing the state of modern medicine."
Cutting edge companies are targeting products that fit in the vision of where healthcare is heading, as opposed to where it is now. They have realized it is not just about innovations to their products, but the business model as well. Decisions are not made purely on clinical efficacy, but must also take into account factors like ease of use, reimbursement, long term cost of care, wellness, prevention and other advanced healthcare outcome measures.
The 2012 United States Medical Devices Outlook is part of the Advanced Medical Technologies Growth Partnership Services program, which also includes research in the following markets:
- Surgical Tools and Medical Implants
- Medical Imaging Systems
- Patient Monitoring and Diagnostic Tools
- Chronic and Acute Disease Management Treatment Products
All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
2012 United States Medical Devices Outlook
SOURCE Frost & Sullivan